We are live on ! Find out more
LFCR icon

Lifecore Biomedical

111 hedge funds and large institutions have $296M invested in Lifecore Biomedical in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 50 increasing their positions, 37 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 37

3% more capital invested

Capital invested by funds: $287M → $296M (+$9.48M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

11% less funds holding

Funds holding: 125111 (-14)

58% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 24

79% less call options, than puts

Call options by funds: $28K | Put options by funds: $132K

Holders
111
Holders Change
-14
Holders Change %
-11.2%
% of All Funds
3.22%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
10
Increased
50
Reduced
37
Closed
24
Calls
$28K
Puts
$132K
Net Calls
-$104K
Net Calls Change
+$450K
Name Holding Trade Value Shares
Change
Change in
Stake
RhumbLine Advisers
76
RhumbLine Advisers
Massachusetts
$303K
AIG
77
American International Group
New York
$285K -$8.04K -673 -3%
AllianceBernstein
78
AllianceBernstein
Tennessee
$284K -$62.1K -5,200 -18%
PCM
79
Palouse Capital Management
Washington
$278K -$4.48K -375 -2%
BGIM
80
Brandywine Global Investment Management
Pennsylvania
$278K
MLICM
81
Metropolitan Life Insurance Company (MetLife)
New York
$273K
First Trust Advisors
82
First Trust Advisors
Illinois
$267K -$172K -14,395 -39%
Nomura Holdings
83
Nomura Holdings
Japan
$256K -$230K -19,228 -48%
PCM
84
Prelude Capital Management
New York
$243K +$9K +754 +4%
Invesco
85
Invesco
Georgia
$236K -$84.6K -7,087 -27%
PAM
86
Paradigm Asset Management
New York
$235K
CCM
87
Coldstream Capital Management
Washington
$222K +$79.2K +6,630 +57%
Swiss National Bank
88
Swiss National Bank
Switzerland
$216K -$131K -11,000 -38%
VRS
89
Virginia Retirement Systems
Virginia
$202K -$10.7K -900 -5%
Citigroup
90
Citigroup
New York
$166K +$162K +13,582 +12,236%
Susquehanna International Group
91
Susquehanna International Group
Pennsylvania
$165K -$41K -3,436 -20%
LSV Asset Management
92
LSV Asset Management
Illinois
$157K
Asset Management One
93
Asset Management One
Japan
$155K +$153K +12,800 New
Acadian Asset Management
94
Acadian Asset Management
Massachusetts
$153K -$96.6K -8,094 -39%
ACH
95
ArrowMark Colorado Holdings
Colorado
$147K +$145K +12,109 New
Two Sigma Investments
96
Two Sigma Investments
New York
$142K +$141K +11,771 New
Bank of Montreal
97
Bank of Montreal
Ontario, Canada
$131K +$69.7K +5,835 +117%
U
98
UBS
Switzerland
$89K +$46.1K +3,861 +110%
Barclays
99
Barclays
United Kingdom
$40K +$4.26K +357 +12%
IA
100
Icon Advisers
Colorado
$21K +$20.3K +1,700 New

LFCR Hedge Fund Activity: Q4 2013 in Review

111 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2013, worth a combined $296M — up 3.3% from $287M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of LFCR and 10 opened new positions — a net loss of 14 holders — while 37 trimmed existing stakes and 50 added.

The largest buyer was Ariel Investments, adding an estimated $12.9M. The largest seller was Fidelity Investments, exiting entirely with an estimated $7.72M sold.

  • 111 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2013, down from 125 in Q3 2013.
  • Funds reported $296M of Lifecore Biomedical stock for Q4 2013, up 3.3% quarter-over-quarter.
  • 10 funds opened new Lifecore Biomedical positions in Q4 2013 and 24 closed out, a net change of -14 holders.
  • The largest Lifecore Biomedical buyer in Q4 2013 was Ariel Investments, an estimated $12.9M added.
  • The largest Lifecore Biomedical seller in Q4 2013 was Fidelity Investments, an estimated $7.72M sold.

Based on aggregated 13F filings for Q4 2013.